Russian biotechnology company Biocad has announced the launch of clinical trials for "BCD-225", a new innovative drug for the treatment of bladder cancer.
Biocad's media office explained that the main objective of the first phase of clinical trials is to assess the drug's safety and tolerability.
The company's statement read: "The clinical study is an open, non-comparative Phase 1 study and is being conducted only in Russia. The main objective of this phase is to assess the drug's safety and tolerability."
According to a source in the company, the trial will also determine the expected therapeutic dose of the drug when administered intravesically in conjunction with standard treatment, the anti-tumor BCG (Bacillus Calmette-Guérin) vaccine, for patients with non-muscle-invasive bladder cancer.
The source explained that combining BCD-225 and BCG would enhance the local anti-tumor immune response in high-risk non-invasive bladder cancer patients, who still have a high risk of disease recurrence or progression.
Bladder cancer is one of the most common cancers, ranking seventh among all malignant tumors in men and seventeenth among women, according to international data.
Biocad explained that doctors diagnose about 75% of cases of non-invasive muscle disease at the first visit.
